辉瑞Ponsegromab治疗癌症恶液质的 II 期临床研究达到主要终点

界面
22 Sep 2024

9月22日,辉瑞公司官微宣布,其针对生长分化因子-15(GDF-15)的单克隆抗体ponsegromab的II期临床研究达到了主要终点,即与安慰剂相比,接受ponsegromab治疗的癌症恶液质和GDF-15水平升高患者的体重与基线相比发生了显著变化。恶液质是一种常见的、危及生命的消耗性疾病,会严重影响癌症患者的生活质量。基于这些积极的结果,辉瑞正在与监管机构讨论后期开发计划,目标是在2025年...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10